BR112022020278A2 - Compostos inibidores de chk1, formas sólidas cristalinas, processos para preparar os mesmos e composição farmacêutica - Google Patents
Compostos inibidores de chk1, formas sólidas cristalinas, processos para preparar os mesmos e composição farmacêuticaInfo
- Publication number
- BR112022020278A2 BR112022020278A2 BR112022020278A BR112022020278A BR112022020278A2 BR 112022020278 A2 BR112022020278 A2 BR 112022020278A2 BR 112022020278 A BR112022020278 A BR 112022020278A BR 112022020278 A BR112022020278 A BR 112022020278A BR 112022020278 A2 BR112022020278 A2 BR 112022020278A2
- Authority
- BR
- Brazil
- Prior art keywords
- processes
- chk1
- preparing
- pharmaceutical composition
- crystalline forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006305P | 2020-04-07 | 2020-04-07 | |
| PCT/US2021/025977 WO2021207210A1 (en) | 2020-04-07 | 2021-04-06 | Methods for synthesis of chk1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020278A2 true BR112022020278A2 (pt) | 2022-12-06 |
Family
ID=78024095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020278A BR112022020278A2 (pt) | 2020-04-07 | 2021-04-06 | Compostos inibidores de chk1, formas sólidas cristalinas, processos para preparar os mesmos e composição farmacêutica |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12606550B2 (https=) |
| EP (1) | EP4132922A4 (https=) |
| JP (1) | JP2023523165A (https=) |
| CN (2) | CN115443271A (https=) |
| BR (1) | BR112022020278A2 (https=) |
| CA (1) | CA3174222A1 (https=) |
| TW (1) | TW202204348A (https=) |
| WO (1) | WO2021207210A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773778A (en) | 1972-01-24 | 1973-11-20 | Squibb & Sons Inc | Sulfur derivatives of pyrazolo (3,4-b)pyridines |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| EP1248869A2 (en) * | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| ATE369854T1 (de) | 2001-10-19 | 2007-09-15 | Ortho Mcneil Pharm Inc | 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs |
| BR0213562A (pt) | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| JP2005515173A (ja) | 2001-10-31 | 2005-05-26 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ピリミド［４，５−ｂ］インドール誘導体 |
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7202244B2 (en) | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| WO2005011597A2 (en) | 2003-07-29 | 2005-02-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| AU2004279427B2 (en) | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP4845736B2 (ja) | 2003-10-14 | 2011-12-28 | アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ | プロテインキナーゼ阻害剤 |
| US7691866B2 (en) | 2003-10-16 | 2010-04-06 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase |
| US20050096324A1 (en) | 2003-11-05 | 2005-05-05 | Zhi-Fu Tao | Macrocyclic kinase inhibitors |
| US7163939B2 (en) | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| CA2561831A1 (en) | 2004-04-13 | 2005-12-22 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| CN1243033C (zh) | 2004-07-15 | 2006-02-22 | 合肥工业大学 | 一种通过内增韧制备薄膜级聚l－乳酸共聚物的方法 |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CA2604284A1 (en) | 2005-04-28 | 2006-11-02 | Supergen, Inc. | Protein kinase inhibitors |
| CN101213187B (zh) | 2005-06-28 | 2012-06-06 | 塞诺菲-安万特股份有限公司 | 作为rho-激酶抑制剂的异喹啉衍生物 |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| JP5052518B2 (ja) | 2005-10-06 | 2012-10-17 | シェーリング コーポレイション | プロテインキナーゼインヒビターとしてのピラゾロピリミジン |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0616747D0 (en) | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
| SA07280004B1 (ar) | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
| MX2009005964A (es) | 2006-12-27 | 2009-06-15 | Sanofi Aventis | Derivados de isoquinolina sustituidos con cicloalquilamina. |
| EP2727909A1 (en) | 2007-03-16 | 2014-05-07 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| US20100249112A1 (en) | 2007-05-25 | 2010-09-30 | Astrazeneca R&D | Combination of chk and parp inhibitors for the treatment of cancers |
| US8618121B2 (en) | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US9000027B2 (en) | 2008-02-04 | 2015-04-07 | Dana-Farber Cancer Institute, Inc. | Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3 |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| US8865726B2 (en) * | 2009-09-03 | 2014-10-21 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| WO2013039854A1 (en) | 2011-09-15 | 2013-03-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| JP6073910B2 (ja) | 2011-11-09 | 2017-02-01 | キャンサー・リサーチ・テクノロジー・リミテッド | ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用 |
| EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
| WO2013103836A2 (en) | 2012-01-05 | 2013-07-11 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
| ES2624307T3 (es) | 2012-05-15 | 2017-07-13 | Cancer Research Technology Ltd | 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo |
| CN102675858A (zh) | 2012-05-22 | 2012-09-19 | 同济大学 | 一种具有形状记忆功能可降解泪管栓塞的制备方法 |
| GB201316526D0 (en) | 2013-09-17 | 2013-10-30 | King S College London | Biomarkers |
| WO2015077602A1 (en) | 2013-11-22 | 2015-05-28 | Fred Hutchinson Cancer Research Center | Methods for identifying therapeutic targets and treating and monitoring cancers |
| WO2015176033A1 (en) | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| EP3347026A4 (en) | 2015-09-09 | 2019-05-08 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY |
| CA3015913A1 (en) | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods of treating cancer |
| WO2018102613A2 (en) | 2016-12-01 | 2018-06-07 | Nantomics, Llc | Tumor antigenicity processing and presentation |
| JP7273791B2 (ja) | 2017-04-10 | 2023-05-15 | シエラ オンコロジー， インコーポレイテッド | 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法 |
| WO2018191299A1 (en) | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth |
| CA3065803A1 (en) | 2017-06-01 | 2018-12-06 | Sierra Oncology, Inc. | Biomarkers and patient selection strategies |
| WO2019012030A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER |
| CA3092079A1 (en) | 2018-02-26 | 2019-08-29 | Sierra Oncology, Inc. | Methods of treatment of cancer comprising chk1 inhibitors |
| CA3135165A1 (en) | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| MX2021013905A (es) | 2019-05-14 | 2022-05-18 | Sierra Oncology Inc | Métodos de tratamiento del cáncer mediante el uso de inhibidores de chk1. |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
-
2021
- 2021-03-29 TW TW110111391A patent/TW202204348A/zh unknown
- 2021-04-06 US US17/995,564 patent/US12606550B2/en active Active
- 2021-04-06 JP JP2022561181A patent/JP2023523165A/ja active Pending
- 2021-04-06 CA CA3174222A patent/CA3174222A1/en active Pending
- 2021-04-06 EP EP21784225.1A patent/EP4132922A4/en active Pending
- 2021-04-06 BR BR112022020278A patent/BR112022020278A2/pt unknown
- 2021-04-06 WO PCT/US2021/025977 patent/WO2021207210A1/en not_active Ceased
- 2021-04-06 CN CN202180027747.4A patent/CN115443271A/zh active Pending
- 2021-04-06 CN CN202510460667.8A patent/CN120441567A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115443271A (zh) | 2022-12-06 |
| TW202204348A (zh) | 2022-02-01 |
| EP4132922A1 (en) | 2023-02-15 |
| WO2021207210A1 (en) | 2021-10-14 |
| CN120441567A (zh) | 2025-08-08 |
| US20230150994A1 (en) | 2023-05-18 |
| JP2023523165A (ja) | 2023-06-02 |
| CA3174222A1 (en) | 2021-10-14 |
| EP4132922A4 (en) | 2024-07-03 |
| US12606550B2 (en) | 2026-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023019797A2 (pt) | Inibidor derivado heterocíclico e método de preparação do mesmo e aplicação do mesmo | |
| EA202090917A1 (ru) | Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение | |
| IL318601A (en) | Improved synthesis of a key intermediate of the KRAS inhibitor compound G12C | |
| PE20211756A1 (es) | FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß | |
| BRPI0710199A2 (pt) | Processo para preparação de inibidores de hiv protease | |
| AU2011295724A8 (en) | 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as NAMPT inhibitors for therapy of diseases such as cancer | |
| CO6311107A2 (es) | Moduladores de inflamacion antioxidantes derivados del acido oleanolico con homologacion c-17 | |
| MX2013002461A (es) | Compuestos y composiciones novedosos para la inhibición de nampt. | |
| MX2019011778A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
| AR121018A1 (es) | Forma en estado sólido de piroxasulfona | |
| BR112023000029A2 (pt) | Método de preparação do composto de fenilisoxazolina | |
| CL2011000296A1 (es) | Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados. | |
| MX2020006387A (es) | Sintesis del cocristal 1:1:1 de 1-ciano-2-(4-ciclopropil-bencil)-4 -(beta-d-glucopiranos-1-il)-benceno, l-prolina y agua. | |
| MX2025000971A (es) | Proceso para la sintesis del acido (s)-3-amino-4-(difluorometilenil)ciclopent-1-eno-1-carboxilico | |
| CY1112645T1 (el) | Πολυμορφο β tου ν-(2-αμινοφαινυλο)-4-[ν-(πυριδινο-3-υλο)μεθοξυκαρβονυλ-αμινομεθυλο] βενζαμιδιου (μs-275) | |
| BR112022020278A2 (pt) | Compostos inibidores de chk1, formas sólidas cristalinas, processos para preparar os mesmos e composição farmacêutica | |
| AU2018316542A1 (en) | Indole derivatives as histone demethylase inhibitors | |
| CL2008003059A1 (es) | Metodo para preparar tigeciclina por formacion de un compuesto intermediario nitrado en presencia de una gas inerte y con aislacion de dicho intermediario | |
| PH12021550144A1 (en) | Process and intermediates for the preparation of bilastine | |
| MX2023000970A (es) | Metodo de preparacion de aminofuranos. | |
| MX2025006444A (es) | Proceso para la sintesis de moduladores de tetrahidrofurano sustituidos de los canales de sodio | |
| CL2023001049A1 (es) | Procedimiento para la fabricación de compuestos orgánicos | |
| BR112021025588A2 (pt) | Processo para a preparação dos inibidores de canal de cloreto clc-1 | |
| BR112012013582A2 (pt) | processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos | |
| SA520412408B1 (ar) | عملية تحضير مركبات ثنائي أريل أوكسي بنزو ديازول غير متجانسة مزدوجة الاستبدال |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 401/12 Ipc: C07D 401/12 (2006.01), A61P 35/00 (2006.01) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |